Monument Capital Management Purchases 28,511 Shares of Halozyme Therapeutics, Inc. $HALO

Monument Capital Management acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 3rd quarter, HoldingsChannel.com reports. The firm acquired 28,511 shares of the biopharmaceutical company’s stock, valued at approximately $3,148,000.

A number of other large investors have also recently bought and sold shares of HALO. Bank of America Corp DE acquired a new position in Halozyme Therapeutics during the second quarter worth $214,504,000. William Blair Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the second quarter worth about $196,540,000. Congress Asset Management Co. boosted its stake in shares of Halozyme Therapeutics by 85.6% during the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after acquiring an additional 1,052,509 shares in the last quarter. Royal London Asset Management Ltd. increased its holdings in shares of Halozyme Therapeutics by 12.4% during the 2nd quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock valued at $141,732,000 after acquiring an additional 200,262 shares during the last quarter. Finally, First Trust Advisors LP increased its holdings in shares of Halozyme Therapeutics by 46.5% during the 1st quarter. First Trust Advisors LP now owns 1,482,340 shares of the biopharmaceutical company’s stock valued at $95,804,000 after acquiring an additional 470,558 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: A Dutch patent court ruled that Merck’s subcutaneous Keytruda infringes a Halozyme patent and ordered MSD to stop manufacturing, selling, importing, or stocking the product in eight European markets. The injunction strengthens Halozyme’s intellectual-property position and could help protect future royalty opportunities. Halozyme Wins Injunction Stopping Manufacture and Sale of Merck’s Keytruda SC in Multiple European Markets
• Positive Sentiment: Halozyme expanded its ENHANZE collaboration with argenx to include two additional exclusive targets, bringing the total to eight. The deal expands the potential for development milestones, licensing payments, and royalties while supporting long-term revenue growth. HALO Expands ENHANZE Collaboration and Licensing Deal With argenx
• Neutral Sentiment: Halozyme CEO Helen Torley sold 20,000 shares for approximately $2.19 million at an average price of $109.40, reducing her holdings by 2.54%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary signal about management’s outlook. Halozyme Therapeutics CEO Helen Torley Sells 20,000 Shares
• Negative Sentiment: JPMorgan raised its price target for HALO from $70 to $78 but retained a “neutral” rating. The target remains substantially below the referenced $109.84 share price, suggesting the bank believes the stock’s legal and growth prospects may already be reflected in its valuation. JPMorgan Raises Halozyme Price Target

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,852 shares of company stock worth $13,538,046 over the last three months. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics Trading Down 0.9%

Halozyme Therapeutics stock opened at $109.84 on Friday. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $116.85. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The firm has a market capitalization of $12.47 billion, a PE ratio of 32.79, a PEG ratio of 0.42 and a beta of 0.88. The business’s 50-day simple moving average is $105.64 and its 200-day simple moving average is $82.86.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HALO. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Wells Fargo & Company increased their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. Finally, Citizens Jmp upped their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $94.00.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.